A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Eszopiclone tablets





DailyMed - ESZOPICLONE- eszopiclone tablet, film coated

7/17/2014
04:31 | Author: Christina Harris

Eszopiclone tablets
DailyMed - ESZOPICLONE- eszopiclone tablet, film coated

NDC Code(s): , , ; Packager: Teva Pharmaceuticals USA Inc. Category: HUMAN PRESCRIPTION DRUG LABEL.

Use in Patients with Depression.

Most commonly observed adverse reactions (incidence ≥ 2%) were unpleasant taste, headache, somnolence, respiratory infection, dizziness, dry mouth, rash, anxiety, hallucinations, and viral infections ( 6.1 ).

In some patients, the higher morning blood levels of eszopiclone tablets following use of the 2 mg or 3 mg dose increase the risk of next day impairment of driving and other activities that require full alertness [ see Warnings and Precautions ( 5.1 ) ].

Comments (1)Read more



Teva39s generic of Lunesta Tablets, CIV Eszopiclone Tablets CIV

5/16/2014
02:22 | Author: Evan Martin

Eszopiclone tablets
Teva39s generic of Lunesta Tablets, CIV Eszopiclone Tablets CIV

Save money on your Lunesta Tablets, CIV prescription by switching to Teva's FDA-approved generic version, Eszopiclone Tablets CIV.

Smart-Health.com gives you the tools to help make smart decisions about your health including useful information about the value of generic medications. Learn More.

2014 Teva Pharmaceuticals USA.

Download the 2014 Teva Product Catalog.

About Teva Generics Patients Healthcare Professionals Trade Partners.

Learn more about employment opportunities at Teva. Grow with the best.

Comments (0)

Drug Safety Labeling Changes Lunesta (eszopiclone) Tablets

3/15/2014
12:33 | Author: Kate Thompson

Eszopiclone tablets
Drug Safety Labeling Changes Lunesta (eszopiclone) Tablets

Sections Modified, Summary of Changes to Contraindications and Warnings. WARNINGS. First paragraph (second sentence changed to a bold print type):.

Severe Anaphylactic and Anaphylactoid Reactions (new subsection).

(See highlighted label for revised text.).

The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. PRECAUTIONS MEDICATION GUIDE (new) WARNINGS (second paragraph).

Page Last Updated: 06/19/2009 Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Summary View WARNINGS.

These events can occur in sedative-hypnotic-naïve as well as in sedative-hypnotic-experienced persons. Amnesia and other neuropsychiatric symptoms may occur unpredictably. As with sleep-driving, patients usually do not remember these events. Although behaviors such as sleep-driving may occur with Lunesta alone at therapeutic doses, the use of alcohol and other CNS depressants with Lunesta appears to increase the risk of such behaviors, as does the use of Lunesta at doses exceeding the maximum recommended dose. .Complex behaviors such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported. In primarily depressed patients, worsening of depression, including suicidal thoughts and actions (including completed suicides), have been reported in association with the use of sedative/hypnotics. Due to the risk to the patient and the community, discontinuation of Lunesta should be strongly considered for patients who report a “sleep-driving” episode. Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic.

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including Lunesta.

Comments (0)

STEPS Eszopiclone (Lunesta) for Treatment of Transient and

11/24/2014
08:36 | Author: Devin Garcia

Eszopiclone tablets
STEPS Eszopiclone (Lunesta) for Treatment of Transient and

A one-month supply of eszopiclone (1-, 2-, or 3-mg tablets) will cost patients approximay $111. This price is slightly higher than the cost of.

Sleep quality, next-day daytime ability to function, daytime alertness, and sense of physical well-being also were improved. There has been little published research on the effectiveness of eszopiclone in patients who have difficulty sleeping. One study 3 analyzed the use of eszopiclone for six months in 791 adult patients with chronic insomnia (age = 21 to 69 years; 63 percent were women). After one week of therapy, eszopiclone-treated patients fell asleep a mean of 37 minutes faster, had 0.6 fewer nighttime awakenings, and slept 50 minutes longer than placebo-treated patients.

Comments (4)Read more

Teva Announces Launch of Generic Lunesta Tablets in the United

9/23/2014
06:15 | Author: Kate Thompson

Eszopiclone tablets
Teva Announces Launch of Generic Lunesta Tablets in the United

Lunesta Tablets, marketed by Sunovion Pharmaceuticals , had annual sales of approximay $852 million in the United States , according to IMS data as of.

15, 2014-- Teva Pharmaceutical Industries Ltd. JERUSALEM --(BUSINESS WIRE)--Apr. (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States.

Securities and Exchange Commission.

Comments (5)Read more